Alternatives to Traditional Per-Oral Endoscopy for Screening - 20/12/17
, Rebecca C. Fitzgerald, MD bRésumé |
Barrett’s esophagus (BE) predisposes patients to esophageal adenocarcinoma. 3 to 6% of individuals with gastro-esophageal reflux disease are estimated to have BE but only 20 to 25% of BE patients are currently diagnosed. The current gold standard for diagnosis of BE is per-oral upper GI endoscopy. As this is not suitable for large-scale screening, a number of alternative methods are currently being investigated: transnasal and video capsule endoscopy, endomicroscopy, cell collection devices like the cytosponge and biomarkers. Some of these are promising, however, well powered studies carried out in relevant screening populations are needed.
Le texte complet de cet article est disponible en PDF.Keywords : Barrett’s esophagus, Esophageal adenocarcinoma, Screening, Endoscopy, Cell collection, Biomarkers, Transnasal endoscopy, Video capsule endoscopy
Plan
| Disclosure Statement: The authors disclose the following: R.C. Fitzgerald holds patents on the Cytosponge technology, which has been licensed by MRC Technology to Covidien GI Solutions (now Medtronic). R.C. Fitzgerald has no direct financial arrangement with Metronic. J. Offman has no conflict of interest to declare. |
Vol 27 - N° 3
P. 379-396 - juillet 2017 Retour au numéro
Article précédent
- Who Deserves Endoscopic Screening for Esophageal Neoplasia?
- Christopher H. Blevins, Prasad G. Iyer
- Effectiveness and Cost-Effectiveness of Endoscopic Screening and Surveillance
- Nina Saxena, John M. Inadomi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?